FDA Grants Breakthrough Device Designation to ORTHOSON's Bio-Structural Gel
This designation assures enhanced FDA cooperation and priority regulatory review of the company's novel medical solution for back pain due to degenerative disc diseaseOXFORD, England--(BUSINESS WIRE)--ORTHOSON, a medtech innovator developing a portfolio of novel treatments for back pain, today announced that its Bio...
United Kingdom United States Mey Saied University Of Sheffield Drug Administration Sheffield Hallam University
Source: pharmiweb.com